My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
  • Your browser version may not work well with NCBI's Web applications. More information here...

Results: 1 to 20 of 109

1.

Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.

Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ.

Breast Cancer Res. 2009;11(3):R31. Epub 2009 May 22.PMID: 19463150 [PubMed - indexed for MEDLINE]Related articlesFree article

2.

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

JAMA. 2006 Jun 7;295(21):2492-502.PMID: 16757721 [PubMed - indexed for MEDLINE]Related articlesFree article

3.

Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.

Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, Strom BL, McDonald JA, Press MF, Bernstein L.

Cancer Res. 2010 Jan 15;70(2):575-87. Epub 2010 Jan 12.PMID: 20068186 [PubMed - indexed for MEDLINE]Related articles

4.

Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.

Parise CA, Bauer KR, Brown MM, Caggiano V.

Breast J. 2009 Nov-Dec;15(6):593-602. Epub 2009 Sep 17.PMID: 19764994 [PubMed - indexed for MEDLINE]Related articles

5.

Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.

Phipps AI, Malone KE, Porter PL, Daling JR, Li CI.

Cancer. 2008 Oct 1;113(7):1521-6.PMID: 18726992 [PubMed - indexed for MEDLINE]Related articlesFree article

6.

Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Phipps AI, Malone KE, Porter PL, Daling JR, Li CI.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2078-86. Epub 2008 Jul 29.PMID: 18664548 [PubMed - indexed for MEDLINE]Related articlesFree article

7.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. Epub 2009 May 12.PMID: 19436038 [PubMed - indexed for MEDLINE]Related articlesFree article

8.

The epidemiology of triple-negative breast cancer, including race.

Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW.

Cancer Causes Control. 2009 Sep;20(7):1071-82. Epub 2009 Apr 3.PMID: 19343511 [PubMed - indexed for MEDLINE]Related articles

9.

Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.

Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD.

Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):413-9.PMID: 10350436 [PubMed - indexed for MEDLINE]Related articlesFree article

10.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.PMID: 17950079 [PubMed - indexed for MEDLINE]Related articles

11.

Second primary breast cancer occurrence according to hormone receptor status.

Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA.

J Natl Cancer Inst. 2009 Aug 5;101(15):1058-65. Epub 2009 Jul 9.PMID: 19590058 [PubMed - indexed for MEDLINE]Related articles

12.

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V.

Cancer. 2007 May 1;109(9):1721-8.PMID: 17387718 [PubMed - indexed for MEDLINE]Related articlesFree article

13.

Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status.

Rusiecki JA, Holford TR, Zahm SH, Zheng T.

Cancer Detect Prev. 2005;29(5):419-26. Epub 2005 Sep 23.PMID: 16185815 [PubMed - indexed for MEDLINE]Related articles

14.

Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer.

Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):479-85. Epub 2009 Feb 3.PMID: 19190139 [PubMed - indexed for MEDLINE]Related articlesFree article

15.

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.

Hum Pathol. 2006 Sep;37(9):1217-26. Epub 2006 Jul 18.PMID: 16938528 [PubMed - indexed for MEDLINE]Related articles

16.

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW.

Breast Cancer Res Treat. 2009 Jan;113(2):357-70. Epub 2008 Mar 7.PMID: 18324472 [PubMed - indexed for MEDLINE]Related articles

17.

Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.

Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R.

Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1175-81.PMID: 14652277 [PubMed - indexed for MEDLINE]Related articlesFree article

18.

Risk factors for triple-negative breast cancer in women under the age of 45 years.

Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1157-66. Epub 2009 Mar 31.PMID: 19336554 [PubMed - indexed for MEDLINE]Related articles

19.

A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.

Xing P, Li J, Jin F.

Med Oncol. 2009 Sep 23. [Epub ahead of print]PMID: 19771534 [PubMed - as supplied by publisher]Related articles

20.

Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.

Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.

Cancer. 2008 Mar 1;112(5):995-1000.PMID: 18098228 [PubMed - indexed for MEDLINE]Related articlesFree article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed
Write to the Help Desk